Teriparatide 0.25 Mg Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 0.25 mg/ ml
Reference Brands: Terrosa (EU)
Category:
Osteoporosis
It is used to treat bone loss (osteoporosis) in men and postmenopausal women at high risk of fracture. It is a synthetic form of the parathyroid hormone naturally produced in the body. This Injection is the only drug that works on bone formation, while the other drugs work on bone resorption.
TERIPARATIDE 0.25 mg Injection is available in Injection
and strengths such as 0.25 mg/ ml.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, TERIPARATIDE 0.25 mg Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
TERIPARATIDE 0.25 mg Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Used in the treatment of bone loss (osteoporosis) in men and postmenopausal women.
Teriparatide is a medication used in the treatment and management of osteoporosis, belonging to the anabolic class of osteoporosis therapies. It is a recombinant form of the first 34 amino acids of human parathyroid hormone (PTH) and functions as a potent osteoanabolic agent. Unlike continuous high levels of PTH, which can lead to bone resorption, intermittent low-dose administration of teriparatide stimulates bone formation more than resorption, increasing bone density and strength.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing